Eli Lilly's Zepbound Beats Novo Nordisk's Wegovy in First Head-to-Head Study -- WSJ
Express News | Lilly: At 72 Weeks, Zepbound Beat Wegovy on Both Primary Endpoint, All Five Key Secondary Endpoints in Trial
Express News | Lilly's Zepbound (Tirzepatide) Superior to Wegovy (Semaglutide) in Head-to-Head Trial Showing an Average Weight Loss of 20.2% Vs. 13.7%
Express News | Lilly: In Phase 3B Trial, Zepbound Provided a 47% Greater Relative Weight Loss Vs Wegovy
Express News | Lilly: In Phase 3B Trial, Participants Using Zepbound Lost 50.3 Lbs. (22.8 Kg) and Participants on Wegovy Lost 33.1 Lbs. (15.0 Kg)
Express News | Lilly: Commonly Reported Adverse Events in Surmount-5 for Zepbound & Wegovy Were Gastrointestinal-Related, Generally Mild to Moderate in Severity
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
